Illumina, a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function, has appointed Nicholas Naclerio to the position of senior vice president of corporate development. He will be reporting to Jay Flatley, president and CEO.
Dr Naclerio will be responsible for all corporate and business development activities, including licensing, strategic planning and acquisitions.
Before joining Illumina, Dr Naclerio served as co-founder and executive chairman of Quanterix, focusing on high-value clinical diagnostics measuring rare serum proteins. He had raised $15m in venture financing to launch the company, and invested in and raised financing for several other biotech and diagnostics companies, including Boreal Genomics, O-Link Bioscience and Fluxion Bioscience.
Dr Naclerio had previously served as executive chairman of True Materials, a particle array technology company, and president and CEO of ParAllele BioScience, a provider of solutions for large-scale genetics research, both of which were later sold to Affymetrix.
Mr Flatley said: “Nick has a long and distinguished track record building successful businesses and commercializing promising scientific and technological innovations in the diagnostics, biotech and other high-tech areas. He brings to Illumina a unique combination of strategic perspective, business leadership and investment acumen that will be instrumental to achieving our growth objectives in life sciences, molecular diagnostics and consumer genomics.”